Specialty Pharmaceutical Industry - 2011 Yearbook - GBI Research Reports

Specialty Pharmaceutical Industry - 2011 Yearbook

Specialty Pharmaceutical Industry - 2011 Yearbook - GBI Research Reports
Specialty Pharmaceutical Industry - 2011 Yearbook
Published May 24, 2011
168 pages — Published May 24, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's 'Specialty Pharmaceutical Industry - 2011 Yearbook essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimers disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

Scope

The report covers -
- Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.
- Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimers disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.
- Data and analysis on the specialty pharmaceutical market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

  
Source:
Document ID
GBIHC078MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents39
  List of Tables63
  List of Figures93
Specialty Pharmaceutical Market- 2011 Yearbook: Introduction121
  Scope121
  GBI Research Report Guidance121
Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market1318
  Disease Overview131
  Market Overview141
  Global HIV Therapeutics Market: Market Characterization141
    Market Forecasts142
    Annual Cost of Therapy162
    Usage Patterns182
      Diseased Population201
      Treatment Seeking Population211
      Diagnosis Population221
      Prescription Population231
    Geographical Distribution242
  HIV Therapeutics Market: Drivers and Restraints261
    Market Drivers261
      Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations261
      New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake271
      Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering the Impact of Generics281
      HIV Therapy and Switch to New Drugs281
    Market Restraints291
      Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions291
      Social Stigma Associated with HIV Leads to a Low Rate of Treatment Seeking; Impacting the Overall Customer Base301
      Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes301
Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder3110
  Disease Overview311
  Market Overview311
  Age Related Macular Degenerative Disorder: Market Characterization321
    Market Forecasts321
    Geographical Distribution331
    Annual Cost of Therapy341
    Usage Patterns351
      Diseased Population361
      Treatment Seeking Population371
      Diagnosis Population381
      Prescription Population391
  Age Related Macular Degenerative Disorder: Drivers and Restraints391
    Market Drivers391
      Population Growth391
      Diagnosis Rate401
    Market Restraints401
      Low Treatment Seeking Behavior401
      Availability of Alternative Options401
Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD)4110
  Introduction411
  Attention Deficit Hyperactive Disorder: Market Characterization411
    Market Forecasts412
    Geographical Distribution431
    Annual Cost of Therapy441
    Usage Patterns451
      Diseased Population461
      Treatment Seeking Population471
      Diagnosis Population481
      Prescription Population491
  Attention Deficit Hyperactive Disorder Market: Drivers and Restraints501
    Market Drivers501
      Growing Population501
      Prescription Rate501
    Market Restraints501
      Treatment Seeking Behavior501
      Diagnosis Rate501
      Availability of Alternative Options501
Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimer s Disease5110
  Introduction511
  Alzheimer s disease: Market Characterization511
    Market Forecasts512
    Geographical Distribution531
    Annual Cost of Therapy541
    Usage Patterns551
      Diseased Population561
      Treatment Seeking Population571
      Diagnosis Population581
      Prescription Population591
  Alzheimer s Disease Market: Drivers and Restraints601
  Market Drivers601
    Aging population601
  Market Restraints601
    Treatment Seeking Behavior601
    Diagnosis rate601
    Pricing601
Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer6110
  Introduction611
  Colorectal Cancer: Market Characterization611
    Market Forecasts612
    Geographical Distribution631
    Annual Cost of Therapy641
    Usage Patterns651
      Diseased Population661
      Treatment Seeking Population671
      Diagnosis Population681
      Prescription Population691
  Colorectal Cancer Market: Drivers and Restraints701
    Market Drivers701
      Treatment usage patterns701
      Annual cost of therapy drivers701
    Market Restraints701
      Patient Volume701
Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis7110
  Introduction711
  Rheumatoid Arthritis: Market Characterization711
    Market Forecasts712
    Annual Cost of Therapy731
    Treatment Usage Patterns741
      Diseased Population751
      Treatment Seeking Population761
      Diagnosis Population762
      Prescription Population781
    Geographical Distribution791
  Rheumatoid Arthritis Market: Drivers and Restraints801
    Market Drivers801
      High incidence and prevalence rate801
    Market Restraints801
      Low Patient affordability801
      Availability of alternative options801
Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy8110
  Introduction811
  Epilepsy: Market Characterization811
    Market Forecasts812
    Geographical Distribution831
    Annual Cost of Therapy841
    Usage Patterns851
      Diseased Population861
      Treatment Seeking Population871
      Diagnosis Population881
      Prescription Population891
  Epilepsy Market: Drivers and Restraints901
    Market Drivers901
    Market Restraints901
      Low treatment seeking behavior901
      Low diagnosis rate and misdiagnosis901
      Pricing901
Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma9111
  Introduction911
  Glaucoma: Market Characterization911
    Market Forecasts912
    Geographical Distribution931
    Annual Cost of Therapy941
    Usage Patterns951
      Diseased Population961
      Treatment Seeking Population971
      Diagnosis Population981
      Prescription Population991
  Glaucoma Market: Drivers and Restraints1001
    Drivers of the Glaucoma Market1001
      Eye Diseases Expected to Grow Across Developed Countries1001
      Improved Diagnostic Equipment to Detect Disease at an Earlier Stage1001
    Barriers for the Glaucoma Market1001
      Low Treatment Seeking Rate and Compliance1001
      Patent Expiries of Major Anti-Glaucoma Products1011
Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis10240
  Specialty Pharmaceutical Pipeline: HIV market1051
  Molecule Profile for Promising Drugs under Clinical Development: HIV1061
    Rilpivirine hydrochloride (TMC278)1061
      Overview1061
      Efficacy1061
      Safety1061
      Clinical Study Details1061
    Elvitegravir1071
      Overview1071
      Efficacy1071
      Safety1071
      Clinical Study Details1071
    Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad)1081
      Overview1081
      Efficacy1081
      Safety1081
      Clinical Study Details1081
    Racivir1091
      Overview1091
      Efficacy1091
      Safety1091
      Clinical Study Details1091
    Apricitabine (ATC)1101
      Overview1101
      Efficacy1101
      Safety1101
      Clinical Study Details1101
    Tesamorelin1111
      Overview1111
      Efficacy1111
      Safety1111
      Clinical Study Details1111
  Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration1121
  Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration1131
    VEGF Trap-Eye1131
      Overview1131
      Efficacy1131
      Safety Profile1131
      Clinical Study Details1131
  Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder1141
  Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder1151
    ABT-894 (Sofinicline)1151
      Overview1151
      Efficacy1151
      Safety1151
      Clinical Study Details1151
    Eltoprazine1151
      Overview1151
      Efficacy1151
      Safety1151
      Clinical Study Details1161
    AZD3480 (TC-1734) (Isopronicline)1161
      Overview1161
      Efficacy1161
      Safety1161
      Clinical Study Details1161
  Specialty Pharmaceutical Pipeline: Alzheimer s Disease1171
  Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer s Disease1181
    Bapineuzumab1181
      Overview1181
      Efficacy1181
      Safety1181
      Clinical Study Details1181
    Gammagard1191
      Overview1191
      Efficacy1191
      Safety1191
      Clinical Study Details1191
    Dimebon1201
      Overview1201
      Efficacy1201
      Safety1201
      Clinical Study Details1201
    Rember (Trx0014) (methylthionium chloride)1201
      Overview1201
      Efficacy1201
      Safety1211
      Clinical Study Details1211
  Specialty Pharmaceutical Pipeline: Colorectal Cancer1221
  Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer1231
    Aflibercept1231
      Overview1231
      Efficacy1231
      Safety1231
      Clinical Study Details1231
      Collaboration Agreements1241
      Marketing Rights1241
      Launch Analysis1241
    Brivanib1241
      Overview1241
      Efficacy1241
      Safety1251
      Clinical trials1251
      Collaboration Agreements1251
      Marketing Rights1251
      Launch Analysis1251

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Specialty Pharmaceutical Industry - 2011 Yearbook" May 24, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Specialty-Pharmaceutical-Industry-2011-Yearbook-2115-216>
  
APA:
GBI Research Reports. (2011). Specialty Pharmaceutical Industry - 2011 Yearbook May 24, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Specialty-Pharmaceutical-Industry-2011-Yearbook-2115-216>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.